Gene Therapy | Gene Therapy for Hemophilia | Gene Therapy Research

Ask Me Anything!
Gene Therapy in Hemophilia

View Conference Coverage

Discover Resources

Open Recommended Resources

Conference Coverage

Histopathological characterization of immune-mediated hepatocellular injury following gene therapy in hemophilia

Conference Coverage

Durable efficacy and safety in responders: 5-Year post hoc end-of-study analysis of etranacogene dezaparvovec in the phase 3 HOPE-B trial

Conference Coverage

Improved hFIX and hFVIII expression with ITR-modified AAV vectors in hemophilic mice

Conference Coverage

Evolution Directed Gene Engineered (EDGE) Gain-of-Function Factor VIII Variants Enhance Gene Therapy for Hemophilia A

Latest News

Role of the Nurse Coordinator in Hemophilia Gene Therapy

26 July 2026

An analysis of attitudes toward gene therapy in people with severe hemophilia in Germany, a survey-based cross-sectional study

02 June 2026

Durability of efficacy, safety, and quality of life 5 years after valoctocogene roxaparvovec gene transfer for severe hemophilia A: Final phase 3 GENEr8-1 trial results

27 March 2026

Building a gene editing lexicon: a model for rare and inherited disorders

13 March 2026

An analysis of attitudes toward gene therapy in people with severe hemophilia in Germany, a survey-based cross-sectional study

11 March 2026

CONFERENCE COVERAGE

Efficacy and Safety of Fidanacogene Elaparvovec in Adults with Moderately Severe or Severe Hemophilia B: Updated Results From the Phase 3 BENEGENE-2 Gene Therapy Trial

Efficacy and Safety of Fidanacogene Elaparvovec in Adults with Moderately Severe or Severe Hemophilia B: Updated Results From the Phase 3 BENEGENE-2 Gene Therapy Trial

30 July 2024Highlights From the 32nd Congress of ISTH

Adam Cuker, MD, MS

Health-related Quality-of-Life Outcomes 4 Years After Treatment with Valoctocogene Roxaparvovec

Health-related Quality-of-Life Outcomes 4 Years After Treatment with Valoctocogene Roxaparvovec

24 July 2024Highlights From the 32nd Congress of ISTH

Bella Madan, MD, FRCP, FRCPath

Efficacy and Safety of Valoctocogene Roxaparvovec 4 Years After Gene Transfer in GENEr8-1

Efficacy and Safety of Valoctocogene Roxaparvovec 4 Years After Gene Transfer in GENEr8-1

27 June 2024Highlights From the 32nd Congress of ISTH

Johnny Mahlangu, BSc, MBBCh, MMed, FCPath

About

Supported through educational grants from BioMarin, CSL Behring, Pfizer Inc., Roche, and Spark Therapeutics

Essential SSL